Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
1999-10-29
2010-12-14
Juedes, Amy E (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
Reexamination Certificate
active
07851591
ABSTRACT:
The invention provides methods for conducting cancer immunotherapy and diagnosis using universal tumor associated antigens, such as the telomerase catalytic subunit (hTERT), and methods for identifying and characterizing universal tumor associated antigens.
REFERENCES:
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 6475789 (2002-11-01), Cech et al.
patent: WO 98/04582 (1998-02-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO 99/50392 (1999-10-01), None
patent: WO 00/02581 (2000-01-01), None
Altuvia et al., 1997, Human Immunology, vol. 58: 1-11.
Koopmann et al., 1997, Curr. Opin. Immunol. vol. 9: 80-88.
Bohm et al., “Identification of HLA-A2-Restricted Epitopes of the Tumor-Associated Antigen MUC2 Recognized by Human Cytotoxic T Cells,”International J. of Cancer75:688-693 (1998).
Brunette et al., “Immunotherapy (Cancer): Tumor Antigen Specific Immunotherapy of Cancer: Peptide and Gene Based Modification of Dendritic Cells as Antigen Presenting Cells,”Cancer Biotechnology Weeklyp. 16 (1996).
Celis et al., “Identification of Potential CTL Epitopes of Tumor-Associated Antigen MAGE-1 for Five Common HLA-A Alleles,”Molecular Immunology31:1423-1430 (1994).
Herlyn et al., “Epitope- and Antigen-Specific Cancer Vaccines,”International Review of Immunology7:245-257 (1991).
Brossart, et al. (1998). “Her-2
eu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.”Cancer Research. 58(4):732-736.
Jensen, et al. (1998). “A europium fluoroimmunoassay for measuring peptide binding to MHC class I molecules.”Journal of Immunological Methods. 215(1-2):71-80.
Kawashima, et al. (1998). “The multi-epitope approach for Immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.”Human Immunology. 59(1):1-14.
Kim, at al. (1994). “Specific association of human telomerase activity with immortal cells and cancer.” Science. 266:2011-2015.
Schultze, et al. (1997). “CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.”Journal of Clinical Investigation. 100(11):2757-2765.
Schultze, et al. (1997). “Vaccination as immunotherapy for B cell lymphoma.”Hematological Oncology. 15(3):129-139.
Vonderheide, et al. (1999). “Generation of telomerase-specific HLA-A3-restricted cytotoxic T lymphocytes from patient blood: implications for widely applicable anti-cancer immunotherapy.”Forty-first annual meeting of the American Society of Hematology;, New Orleans. 94(10):677a.
Schultze et al., “Autologous adoptive T cell transfer for a patient with plasma cell leukemia: results of a pilot phase I trial”,Therapy of Chronic Lymphocytic Leukemia and Multiple Myeloma, Abstract #446, p. 109a (1998).
Vonderheide et al., “The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by Cytotoxic T lymphocytes”,Immunity, 10:673-679 (1999).
Alexander et al., “Derivation of HLA-A11/Kbtransgenic Mice”J. Immunol., 159:4753-4761 (1997).
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes”,Science, 274:94-96 (1996).
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”,Nuc. Acids Res., 25(17):3389-3402 (1997).
Anderson et al., “Intracellular Transport of Class I MHC Molecules in Antigen Processing Mutant Cell Lines”,J. Immunol., 151(7):3407-3419 (1993).
Anderson, W.F., “Prospects for Human Gene Therapy”,Science, 226:401-409 (1984).
Aruga et al., “Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells”,Cancer Immunol. Immunother., 41:317-324 (1995).
Ashley et al., “Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors”,J. Exp. Med., 186(7):1177-1182 (1997).
Blomer et al., “Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector”,J. Virol., 71(9):6641-6649 (1997).
Boczkowski et al., “Dendritic Cells Pulsed with RNA are Potent Antigen-presenting Cells in Vitro and in Vivo”,J. Exp. Med., 184:465-472 (1996).
Bohlen et al., “Differentiation of cytotoxicity using target cells labeled with europium and samarium by electroporation”,J. Immunol. Meth., 173:55-62 (1994).
Boon et al., “Tumor anatigens recognized by T lymphocites”,Ann. Rev. Immunol., 12:337-365 (1994).
Brigham et al., “Rapid Communication: in vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle”,Am. J. Med. Sci., 298(4):278-281 (1989).
Broccoli et al., “Telomerase activity in normal and malignant hematopoietic cells”,Proc. Nat'l. Acad. Sci. U.S.A., 92:9082-9086 (1995).
Brodie et al., “In vivo migration and function of transferred HIV-1-specific cytotoxic T cells”,Nat. Med., 5(1):34-41 (1999).
Brossart et al., “Identification of HLA-A2—Restricted T-Cell Epitopes Derived From the MUCI Tumor Antigen for Broadly Applicable Vaccine Therapies”,Blood, 93:4309-4317 (1999).
Brusic et al., “MHCPEP, a database of MHC-binding peptides: update 1997”,Nuc. Acids Res., 26(1):368-371 (1998).
Brusic et al., “Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network”,Bioinformatics, 14(2):121-130 (1998).
Bryan et al., “Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines”,Nat. Med., 3(11):1271-1274 (1997).
Buchovich et al., “Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells”,Mol. Bio. Cell, 7:1443-1454 (1996).
Busch et al., “MHC Class I/Peptide Stability: Implications for Immunodominance, in Vitro Proliferation, and Diversity of Responding CTL”,J. Immunol., 160:4441-4448 (1998).
Callan et al., “Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus in Vivo”,J. Exp. Med., 187:1395-1402 (1998).
Cayouette et al., “Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) Mouse”,Hum. Gene Ther., 8:423-430 (1997).
Cornetta et al., “Gene Transfer into Primates and Prospects for Gene Therapy in Humans”,Nucl. Acid Res. Mol. Biol., 36:311-322 (1987).
Cornette et al., “Periodic variation in side-chain polarities of T-cell antigenic peptides correlates with their structure and activity”,Proc. Nat'l. Acad. Sci. U.S.A., 92:8368-8372 (1995).
Counter et al., “Stabilization of Short Telomeres and Telomerase Activity Accompany Immortalization of Epstein-Barr Virus-Transformed Human B Lymphocytes”,.J. Virol., 68:3410-3414 (1994).
Counter et al., “Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalityc submit of telomerase”,Oncogene., 16:1217-1222 (1998).
De Groot et al., “Prediction of Protein Conformational Freedom From Distance Constraints”,Proteins: Struct. Funct. Genet., 29:240-251 (1997).
DeLisi et al., “T-cell antigenic sites tend to be amphipathic structures”,Proc. Nat'l. Acad. Sci. U.S.A., 82:7048-7052 (1985).
Dunbar et al., “Direct isolation, phenotyping and
Hahn William C.
Nadler Lee M.
Schultze Joachim L.
Vonderheide Robert H.
Dana Farber Cancer Institute, Inc.
Elrifi Ivor R.
Juedes Amy E
Kozakiewicz Cynthia A.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Cancer immunotherapy and diagnosis using universal tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer immunotherapy and diagnosis using universal tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy and diagnosis using universal tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202811